NO20013408L - Use of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for prophylaxis and therapy of cerebral ischemia - Google Patents

Use of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for prophylaxis and therapy of cerebral ischemia

Info

Publication number
NO20013408L
NO20013408L NO20013408A NO20013408A NO20013408L NO 20013408 L NO20013408 L NO 20013408L NO 20013408 A NO20013408 A NO 20013408A NO 20013408 A NO20013408 A NO 20013408A NO 20013408 L NO20013408 L NO 20013408L
Authority
NO
Norway
Prior art keywords
substituted
derivatives
therapy
cerebral ischemia
prophylaxis
Prior art date
Application number
NO20013408A
Other languages
Norwegian (no)
Other versions
NO20013408D0 (en
Inventor
Gerd Steinler
Kurt Schellhaas
Wilfried Lubisch
Uta Holzenkamp
Dorothea Starck
Laszlo Szabo
Franz Emling
Francisco-Javier Garcia-Ladona
Hans Peter Hofmann
Liliane Unger
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO20013408D0 publication Critical patent/NO20013408D0/en
Publication of NO20013408L publication Critical patent/NO20013408L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Anvendelse av forbindelser med formel l G ¿ A----B----Ar (I), hvor substituentene er som definert i beskrivelsen, og deres salter med farmakologisk godtagbare syrer for fremstilling av medikamenter for forebygging og terapi av cerebral ischemi og slag er beskrevet.Use of Compounds of Formula I G ¿A ---- B ---- Ar (I), wherein the substituents are as defined in the specification, and their salts with pharmacologically acceptable acids for the manufacture of drugs for the prevention and therapy of cerebral ischemia and punches are described.

NO20013408A 1999-01-11 2001-07-10 Use of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for prophylaxis and therapy of cerebral ischemia NO20013408L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19900544A DE19900544A1 (en) 1999-01-11 1999-01-11 Use of compounds of formula I for the prophylaxis and therapy of cerebral ischemia
PCT/EP1999/010275 WO2000041697A1 (en) 1999-01-11 1999-12-22 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia

Publications (2)

Publication Number Publication Date
NO20013408D0 NO20013408D0 (en) 2001-07-10
NO20013408L true NO20013408L (en) 2001-08-21

Family

ID=7893835

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013408A NO20013408L (en) 1999-01-11 2001-07-10 Use of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for prophylaxis and therapy of cerebral ischemia

Country Status (19)

Country Link
EP (1) EP1140099A1 (en)
JP (1) JP2002534467A (en)
KR (1) KR20010101440A (en)
CN (1) CN1333685A (en)
AR (1) AR029741A1 (en)
AU (1) AU2285100A (en)
BG (1) BG105688A (en)
BR (1) BR9916888A (en)
CA (1) CA2359390A1 (en)
DE (1) DE19900544A1 (en)
HU (1) HUP0200520A3 (en)
IL (1) IL144145A0 (en)
MX (1) MXPA01006966A (en)
NO (1) NO20013408L (en)
PL (1) PL348916A1 (en)
SK (1) SK9682001A3 (en)
TR (1) TR200102009T2 (en)
WO (1) WO2000041697A1 (en)
ZA (1) ZA200105473B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
EP1667979A4 (en) * 2003-09-23 2007-04-18 Merck & Co Inc Isoquinoline potassium channel inhibitors
JP4324221B2 (en) * 2005-08-26 2009-09-02 株式会社医薬分子設計研究所 Derivatives having PPAR agonist activity
AU2008301884B2 (en) * 2007-09-20 2012-12-20 Cortex Pharmaceuticals, Inc. 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses
MA41168A (en) 2014-12-17 2017-10-24 Acraf NEW ANTIBACTERIAL COMPOUNDS
CN108484594B (en) * 2018-02-09 2020-08-04 福建医科大学 Alkoxy substituted tetrahydropyridopyrimidine compound or available salt thereof, and preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3620643A1 (en) * 1985-06-22 1987-01-22 Sandoz Ag Thiazoles, their preparation and use
DE3831888A1 (en) * 1988-09-20 1990-03-29 Troponwerke Gmbh & Co Kg MEDICINES FOR TREATING APOPLEXIA CEREBRI
JP3036789B2 (en) * 1990-06-22 2000-04-24 三井化学株式会社 Novel heterocyclic compounds and pharmaceutical compositions
DE19746612A1 (en) * 1997-10-22 1999-04-29 Basf Ag New 2-substituted 1,2-benzisothiazole derivatives
DE19747063A1 (en) * 1997-10-24 1999-04-29 Basf Ag New 3-substituted tetrahydropyridopyrimidinone derivatives

Also Published As

Publication number Publication date
JP2002534467A (en) 2002-10-15
SK9682001A3 (en) 2002-03-05
CN1333685A (en) 2002-01-30
BR9916888A (en) 2001-11-20
EP1140099A1 (en) 2001-10-10
NO20013408D0 (en) 2001-07-10
PL348916A1 (en) 2002-06-17
TR200102009T2 (en) 2002-01-21
HUP0200520A2 (en) 2002-07-29
AR029741A1 (en) 2003-07-16
KR20010101440A (en) 2001-11-14
HUP0200520A3 (en) 2003-04-28
IL144145A0 (en) 2002-05-23
CA2359390A1 (en) 2000-07-20
ZA200105473B (en) 2002-10-03
MXPA01006966A (en) 2002-04-10
BG105688A (en) 2002-02-28
DE19900544A1 (en) 2000-07-13
AU2285100A (en) 2000-08-01
WO2000041697A1 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
HK1086256A1 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
TW200502230A (en) Dual nk1/nk3 derivatives
JO2282B1 (en) Oxazol derivatives
MY138352A (en) Benzothiazole derivatives
MXPA04002825A (en) Quinoline derivatives as neuropeptide y antagonists.
IL166412A0 (en) Novel use of benzothiazole derivatives
MX2007000505A (en) Substituted oxindol derivatives and medicaments containing the same.
ATE248837T1 (en) QUINUCLIDINE-ACRYLAMIDE
GEP20084357B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
JO2372B1 (en) Prodrugs of 4-phenyl-pyridine derivatives
NO20060147L (en) Benzimidazole derivatives, compositions containing them, their preparation and their use
NO20060146L (en) Benzimidazole derivatives, compositions containing them, their preparation and their use
NO20052182L (en) New connections
TR199802060T2 (en) Use of aminoisoquinolins and aminopyridine derivatives as anti-inflammatory agents.
NO20013409L (en) Use of pyrimidine derivatives for the prevention and treatment of cerebral ischemia
GEP20084437B (en) Novel lincomycin derivatives possessing antimicrobial activity
ATE389655T1 (en) PYRIMIDINE DERIVATIVES
SE9803773D0 (en) Compounds
NO20013408L (en) Use of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for prophylaxis and therapy of cerebral ischemia
NO20022123L (en) Oxoxazole derivatives for use as inhibitors of phosphodiesterase VII
WO2005053702A3 (en) Anti-inflammatory agents
NO982863L (en) New compounds with analgesic effect
NO20045353L (en) Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
EP2266566A3 (en) Nicotinamide derivatives and their use as therapeutic agents
NO20004075L (en) Substituted pyrimidin-2-yloxy-carboxylic acid derivatives, their preparation and their use as endothelin antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application